Immupharma PLC Exercise of Options (5802Y)
07 Septiembre 2022 - 2:25AM
UK Regulatory
TIDMIMM
RNS Number : 5802Y
Immupharma PLC
07 September 2022
7 September 2022
ImmuPharma plc
("ImmuPharma" or the "Company")
Exercise of Options
ImmuPharma plc (LSE : IMM), the specialist drug discovery and
development company, announces that L1 Capital Global Opportunities
Master Fund ("L1") has exercised Options over 3,000,000 new
ordinary shares of 1p each ("Ordinary Shares") at an exercise price
of 5p per share, for a consideration of GBP150,000.
New Ordinary Shares and Admission
The New Ordinary Shares have been allotted today and are issued
credited as fully paid and will rank pari passu in all respects
with the Company's existing issued ordinary shares.
An application will be made for the New Ordinary Shares to be
admitted to trading on the AIM market ("Admission") of the London
Stock Exchange. It is anticipated that Admission will occur on or
around Monday 12 September 2022.
The New Ordinary Shares represent 0.90% of the Company's
enlarged issued share capital.
Total Shares in Issue
For the purposes of the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority ("DTR"), the Board of
ImmuPharma hereby notifies the market that following Admission, the
Company's total issued share capital will consist of 333,403,115
Ordinary Shares with a nominal value of 1p each.
This figure may be used by Shareholders as the denominator for
the calculations by which they may determine if they are required
to notify their interest in, or a change to their interest in, the
Company under the DTR.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program,
Lupuzor(TM), is a first-in class autophagy immunomodulator which is
in Phase 3 for the treatment of lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases
that share the same autophagy mechanism of action. ImmuPharma and
Alora Pharmaceuticals signed on 28 November 2019, an exclusive
licence and development agreement and trademark agreement for
Lupuzor(TM) to fund a new international Phase 3 trial for
Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOESSLSWWEESEEU
(END) Dow Jones Newswires
September 07, 2022 03:25 ET (07:25 GMT)
Immupharma (AQSE:IMM.GB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immupharma (AQSE:IMM.GB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
